to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

522

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

September 7, 2022

Study Completion Date

April 9, 2027

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

HLX10

HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.

DRUG

nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide

chemotherapeutics

DRUG

Placebo

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY